Intro to COVID-19: Combating Fraudulent Products

This session will discuss the varying authorities FDA has to combat fraudulent products including warning letters, seizures, injunctions, and criminal prosecutions.

Cathy L. Burgess, Partner, Alston & Bird LLP,  Member, FDLI Board of Directors

This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues”on  August 18, 2020.

 

Get Access

$99
  • +$100 for nonmembers

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

 

On-demand content can be played back on most devices.

 

CLE credit is not currently available for pre-recorded sessions.

Related Content